Pfizer – PARP-Inhibitor Combination Treatments: Safety and Efficacy in a rapidly changing metastatic Castration Resistant Prostate Cancer (mCRPC) landscape
Well-being, Health and Biomedical Discovery
Deadlines
Academic Unit: Inquire with unit
Memorial Deadline: Thursday 10th, October 2024
External Deadline: Thursday 17th, October 2024
Description
Update: Increased total available budget from $500,000 to $1,000,000; individual grant maximum increased from $150,000 to $250,000
Pfizer Global Medical Grants & Partnerships (GMGP) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s GMGP competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the specific RFP.
For all independent medical education grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct of the independent education program.
Date RFP Issued: September 3, 2024
Geographic Scope: United States prioritized, Global in-scope
Clinical Area: Prostate Cancer
Link to full RFP: PARP-Inhibitor Combination Treatments: Safety and Efficacy in a rapidly changing metastatic Castration Resistant Prostate Cancer (mCRPC) landscape
Application Due Date: October 17, 2024
Specific Area of Interest: Projects that will be considered for Pfizer support will focus on increasing healthcare professional knowledge and competence in the following areas:
- – Emerging data on efficacy and safety regarding PARPi’s used in the treatment of mCRPC including better understanding of: 1) the mechanism of action and the biological and clincial rationale for PARPi combinations and; 2) clinical safety, treatment sequencing and patient subgroup data, inclusive of previously treated mCRPC patients.
- – Best practices in testing, including how to order and interpret results of biomarkers and genetic mutations (inclusive of BRCA and non-BRCA) and its application to therapy management.
- – Clinical data regarding PARPi combination – vs. mono- therapies and how to mitigate associated side effects for optimal patient care.
– Best practices for initiating guideline concordant care in community healthcare settings for optimal therapy management of PARPi combinations in prostate cancer. - Refer to complete details in the full RFP document. If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Lori Carpenter (Lori.Carpenter@pfizer.com).